{"title":"Investigating experimental vs. Predicted pKa values for PET radiotracer","authors":"","doi":"10.1016/j.ejpb.2024.114430","DOIUrl":null,"url":null,"abstract":"<div><p>The prediction of central nervous system (CNS) active pharmaceuticals and radiopharmaceuticals has experienced a boost by the introduction of computational approaches, like blood–brain barrier (BBB) score or CNS multiparameter optimization values. These rely heavily on calculated pK<sub>a</sub> values and other physicochemical parameters. Despite the inclusion of various physicochemical parameters in online data banks, pK<sub>a</sub> values are often missing and published experimental pK<sub>a</sub> values are limited especially for radiopharmaceuticals. This comparative study investigated the discrepancies between predicted and experimental pK<sub>a</sub> values and their impact on CNS activity prediction scores. The pK<sub>a</sub> values of 46 substances, including therapeutic drugs and PET imaging radiopharmaceuticals, were measured by means of potentiometry and spectrophotometry. Experimentally obtained pK<sub>a</sub> values were compared with <em>in silico</em> predictions (Chemicalize/Marvin). The results demonstrate a considerable discrepancy between experimental and <em>in silico</em> values, with linear regression analysis showing intermediate correlation (R<sup>2</sup><sub>(Marvin)</sub> = 0.88, R<sup>2</sup><sub>(Chemicalize)</sub> = 0.82). This indicates that if one requires an accurate pK<sub>a</sub> value, it is essential to experimentally assess it. This underscores the importance of experimentally determining pK<sub>a</sub> values for accurate drug design and optimization. The study’s data provide a valuable library of reliable experimental pK<sub>a</sub> values for therapeutic drugs and radiopharmaceuticals, aiding researchers in the field.</p></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-08-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S093964112400256X/pdfft?md5=9520f0e4ca8c940dfd6bd6ed92e620c2&pid=1-s2.0-S093964112400256X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S093964112400256X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0
Abstract
The prediction of central nervous system (CNS) active pharmaceuticals and radiopharmaceuticals has experienced a boost by the introduction of computational approaches, like blood–brain barrier (BBB) score or CNS multiparameter optimization values. These rely heavily on calculated pKa values and other physicochemical parameters. Despite the inclusion of various physicochemical parameters in online data banks, pKa values are often missing and published experimental pKa values are limited especially for radiopharmaceuticals. This comparative study investigated the discrepancies between predicted and experimental pKa values and their impact on CNS activity prediction scores. The pKa values of 46 substances, including therapeutic drugs and PET imaging radiopharmaceuticals, were measured by means of potentiometry and spectrophotometry. Experimentally obtained pKa values were compared with in silico predictions (Chemicalize/Marvin). The results demonstrate a considerable discrepancy between experimental and in silico values, with linear regression analysis showing intermediate correlation (R2(Marvin) = 0.88, R2(Chemicalize) = 0.82). This indicates that if one requires an accurate pKa value, it is essential to experimentally assess it. This underscores the importance of experimentally determining pKa values for accurate drug design and optimization. The study’s data provide a valuable library of reliable experimental pKa values for therapeutic drugs and radiopharmaceuticals, aiding researchers in the field.
期刊介绍:
The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.
Topics covered include for example:
Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)
Aspects of manufacturing process design
Biomedical aspects of drug product design
Strategies and formulations for controlled drug transport across biological barriers
Physicochemical aspects of drug product development
Novel excipients for drug product design
Drug delivery and controlled release systems for systemic and local applications
Nanomaterials for therapeutic and diagnostic purposes
Advanced therapy medicinal products
Medical devices supporting a distinct pharmacological effect.